New Antibiotic Treatment Multiple Sclerosis

Featured Article

British researchers have found that 71 percent of patients with relapsing-remitting multiple sclerosis (MS) who were treated with the experimental drug alemtuzumab in a recent study showed no disease activity after four years. This figure is twice the percentage of patients who achieve remission for this period of time who take the standard treatment Rebif, the scientists say.

Read more

More information on "New Antibiotic Treatment Multiple Sclerosis"

From Our Experts

See more SharePosts »

From Our Sources

More on Multiple Sclerosis »